Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786037 | 1.00 | RAB9A (0.54) | RAB9APARP1KDM4EALDH1A1HPGD | |
| SCHEMBL1723847 | 0.88 | RAB9A (0.58) | RAB9APARP1KDM4EALDH1A1HPGD | |
| SCHEMBL29980732 | 0.88 | RAB9A (0.58) | RAB9APARP1KDM4EALDH1A1HPGD | |
| Methane SCHEMBL25344317 | 0.86 | RAB9A (0.56) | RAB9APARP1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL16797856 | 0.86 | RAB9A (0.56) | RAB9APARP1KDM4EALDH1A1HPGD | |
| SCHEMBL31182075 | 0.85 | TDP1 (0.52) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| Formic Acid SCHEMBL9954308 | 0.82 | RAB9A (0.52) | RAB9APARP1KDM4EALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL29810625 | 0.78 | RAB9A (0.49) | RAB9APARP1KDM4EALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL484379 | 0.78 | RAB9A (0.49) | RAB9APARP1KDM4EALDH1A1HPGD | |
| SCHEMBL4724490 | 0.78 | L3MBTL1 (0.58) | RAB9AKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | RAB9A 1227/4885PARP1 2484/4885KDM4E 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.